Department of Clinnical Pharmacy, Tonglu First People's Hospital, Zhejiang, Tonglu, Hangzhou, Zhejiang, China, e-mail:
Department of Orthopedics, Tonglu First People's Hospital, Tonglu, Hangzhou, Zhejiang, China.
J Biol Regul Homeost Agents. 2019;33(2):551-555.
This study aimed to evaluate the clinical efficacy of trastuzumab combined with lapatinib in the treatment of human epidermal growth factor receptor 2 (HER2) positive breast cancer. One hundred and fifty-four patients with breast cancer were randomly divided into a trastuzumab group (group A, 52 cases), a lapatinib group (group B, 48 cases) and a combination group (group C, 54 cases).
本研究旨在评估曲妥珠单抗联合拉帕替尼治疗人表皮生长因子受体 2(HER2)阳性乳腺癌的临床疗效。将 154 例乳腺癌患者随机分为曲妥珠单抗组(A 组,52 例)、拉帕替尼组(B 组,48 例)和联合组(C 组,54 例)。